Share
Market Research Report

BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Segmentation
  • By Service TypeDrug substance/Active Pharmaceutical Ingredient (API) Manufacturing · Drug product/Formulation and Fill-Finish (FDF) · Analytical and Quality Control services · Process development and scale-up/Technology transfer · and Packaging · labeling and ancillary services
  • By Biologic TypeMonoclonal antibodies (mAbs) · Recombinant proteins and enzymes · Vaccines · Cell and gene therapies · Antibody-drug conjugates (ADCs) · and Others (growth factors, cytokines, fusion proteins)
  • By Production SystemMammalian systems (CHO, NS0, HEK) · Microbial systems (E. coli, yeast) · and Alternative/Emerging systems (insect cells, plant, cell-free)
  • By ScalePreclinical/clinical scale manufacturing and Commercial scale manufacturing
  • By Company SizeSmall to Mid-sized Contract Manufacturers and Large Contract Manufacturing Organizations (CMOs/CDMOs)
  • By Therapeutic AreaOncology/Hematology · Immunology and Autoimmune Disorders · Infectious Diseases and Vaccinology · Cardiovascular and Renal Disorders · Neurology and Central Nervous System (CNS) Disorders · Metabolic and Endocrine Disorders (e.g., diabetes, obesity, thyroid) · Respiratory Disorders · and Others (Dermatology, Rare and Orphan Diseases)
  • By GeographyNorth America · Europe · Asia Pacific · Latin America · Middle East · and Africa
  • Published In17 Mar 2026
  • Report CodeCMI8662
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026-2033

Market Segmentation

  • Service Type Insights (Revenue, USD Bn, 2021 - 2033)

    • Drug substance/Active Pharmaceutical Ingredient (API) Manufacturing
    • Drug product/Formulation and Fill-Finish (FDF)
    • Analytical and Quality Control services
    • Process development and scale-up/Technology transfer
    • Packaging, labeling and ancillary services

  • Biologic Type Insights (Revenue, USD Bn, 2021 - 2033)

    • Monoclonal antibodies (mAbs)
    • Recombinant proteins and enzymes
    • Vaccines
    • Cell and gene therapies
    • Antibody-drug conjugates (ADCs)
    • Others (growth factors, cytokines, fusion proteins)

  • Production System Insights (Revenue, USD Bn, 2021 - 2033)

    • Mammalian systems (CHO, NS0, HEK)
    • Microbial systems (E. coli, yeast)
    • Alternative/Emerging systems (insect cells, plant, cell-free)

  • Scale Insights (Revenue, USD Bn, 2021 - 2033)

    • Preclinical/clinical scale manufacturing
    • Commercial scale manufacturing

  • Company Size Insights (Revenue, USD Bn, 2021 - 2033)

    • Small to Mid-sized Contract Manufacturers
    • Large Contract Manufacturing Organizations (CMOs/CDMOs)

  • Therapeutic Area Insights (Revenue, USD Bn, 2021 - 2033)

    • Oncology/Hematology
    • Immunology and Autoimmune Disorders
    • Infectious Diseases and Vaccinology
    • Cardiovascular and Renal Disorders
    • Neurology and Central Nervous System (CNS) Disorders
    • Metabolic and Endocrine Disorders (e.g., diabetes, obesity, thyroid)
    • Respiratory Disorders
    • Others (Dermatology, Rare and Orphan Diseases)

  • Regional Insights (Revenue, USD Bn, 2021 - 2033)

    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa